Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components

Acta Pharmacologica Sinica

Volumn 33, Issue 9, 2012, Pages 1119-1130

  Wu, Wen Yu ^a   Wang, Yi Ping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

cardiovascular activities; lithospermic acid; magnesium lithospermate B (lithospermic acid B or salvianolic acid B); rosmarinic acid; Salvia miltiorrhiza depside salt; traditional Chinese medicine

Indexed keywords

CD36 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; GLUCOSE REGULATED PROTEIN 78; HEME OXYGENASE 1; HERBACEOUS AGENT; INTERCELLULAR ADHESION MOLECULE 1; LITHOSPERMIC ACID; LOW DENSITY LIPOPROTEIN; MAGNESIUM LITHOSPERMATE; NITRIC OXIDE; OXIDOREDUCTASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR BB; PROSTAGLANDIN E2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSMARINIC ACID; SALVIA MILTIORRHIZA DEPSIDE SALT; SALVIANOLIC ACID B; STROMAL CELL DERIVED FACTOR 1ALPHA; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA INTIMA; ATHEROSCLEROSIS; CELL ADHESION; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; CIRCULATION; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; FIRST PASS EFFECT; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIPID OXIDATION; LIPID PEROXIDATION; LIVER FIBROSIS; METABOLOMICS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SALVIA MILTIORRHIZA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUES;

ANIMALS; CARDIOVASCULAR DISEASES; DEPSIDES; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; PLANT EXTRACTS; SALVIA MILTIORRHIZA;

EID: 84866004507     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.126     Document Type: Review

References (111)

1. Li LN. Biologically active components from traditional Chinese medicines. Pure Appl Chem 1998; 70: 547-54.
2. Zhou CX, Luo HW, Niwa M. Studies on isolation and identification of water-soluble constituents of Salvia miltiorrhiza. J Chin Pharm Univ 1999; 30: 411-6.
3. Sun J, Huang SH, Tan BK, Whiteman M, Zhu YC, Wu YJ, et al. Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction. Life Sci 2005; 76: 2849-60. (Pubitemid 40460330)
4. Zhang Q, Liu AD, Huang YS. Clinical non-inferiority trial on treatment of coronary heart disease angina pectoris of Xin-blood stasis syndrome type with lyophilized Salvia salt of lithospermic acid powder for injection. Chin J Integr Med 2006; 12: 12-8.
5. Li X, Yu C, Lu Y, Gu Y, Lu J, Xu W, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of depside salts from Salvia miltiorrhiza in rats. Drug Metab Dispos 2007; 35: 234-9. (Pubitemid 46148735)
6. Li X, Yu C, Sun W, Liu G, Jia J, Wang Y. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 2878-82. (Pubitemid 39576830)
7. Jia JY, Lu YL, Li XC, Liu GY, Li SJ, Liu Y, et al. Pharmacokinetics of depside salts from Salvia miltiorrhiza in healthy Chinese volunteers: A randomized, open-label, single-dose study. Curr Ther Res 2010; 71: 260-71.
8. Gao DY, Han LM, Zhang LH, Fang XL, Wang JX. Bioavailability of salvianolic acid B and effect on blood viscosities after oral administration of salvianolic acids in beagle dogs. Arch Pharm Res 2009; 32: 773-9.
9. Zhang Y, Akao T, Nakamura N, Duan CL, Hattori M, Yang XW, et al. Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat. Planta Med 2004; 70: 138-42. (Pubitemid 38299775)
10. Kim HH, Kim J, Ji HY, Kim YC, Sohn DH, Lee BM, et al. Pharmacokinetics of lithospermic acid B isolated from Salvia miltiorrhiza in rats. J Toxicol Environ Health A 2005; 68: 2239-47. (Pubitemid 41755680)
11. Qiu F, Zhang R, Sun J, Jiye A, Hao H, Peng Y, et al. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 2008; 36: 1308-14. (Pubitemid 351929315)
12. Wang QL, Wu Q, Tao YY, Liu CH, El-Nezami H. Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells. Hepatobiliary Pancreat Dis Int 2011; 10: 502-8.
13. Liu YH, Mo SL, Bi HC, Hu BF, Li CG, Wang YT, et al. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica 2011; 41: 259-80.
14. Watzke A, O'Malley SJ, Bergman RG, Ellman JA. Reassignment of the configuration of salvianolic acid B and establishment of its identity with lithospermic acid B. J Nat Prod 2006; 69: 1231-3. (Pubitemid 44409804)
15. Zhao Y, Hao Y, Ji H, Fang Y, Guo Y, Sha W, et al. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila) 2010; 3: 787-96.
16. Hur KY, Seo HJ, Kang ES, Kim SH, Song S, Kim EH, et al. Therapeutic effect of magnesium lithospermate B on neointimal formation after balloon-induced vascular injury. Eur J Pharmacol 2008; 586: 226-33.
17. Pan CH, Chen CW, Sheu MJ, Wu CH. Salvianolic acid B inhibits SDF-1alpha-stimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor. Vascul Pharmacol 2012; 56: 98-105.
18. Hur KY, Kim SH, Choi MA, Williams DR, Lee YH, Kang SW, et al. Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway. Atherosclerosis 2010; 211: 69-76.
19. Hung HH, Chen YL, Lin SJ, Yang SP, Shih CC, Shiao MS, et al. A salvianolic acid B-rich fraction of Salvia miltiorrhiza induces neointimal cell apoptosis in rabbit angioplasty model. Histol Histopathol 2001; 16: 175-83.
20. Cho YH, Lim EY, Kim JM, Jung M, Lee HC, Seo M, et al. Nonmuscle myosin heavy chain and histone H3 are intracellular binding partners of lithospermic acid B and mediate its antiproliferative effect on VSMCs. Curr Med Chem 2012; 19: 1731-7.
21. Wu YJ, Hong CY, Lin SJ, Wu P, Shiao MS. Increase of Vitamin E Content in LDL and reduction of atherosclerosis in cholesterolfed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza. Arterioscler Thromb Vasc Biol 1998; 18: 481-6. (Pubitemid 28125644)
22. Lin SJ, Lee IT, Chen YH, Lin FY, Sheu LM, Ku HH, et al. Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPS-treated human aortic smooth muscle cells. J Cell Biochem 2007; 100: 372-84.
23. Chen YL, Hu CS, Lin FY, Chen YH, Sheu LM, Ku HH, et al. Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta. J Cell Biochem 2006; 98: 618-31.
24. Yang TL, Lin FY, Chen YH, Chiu JJ, Shiao MS, Tsai CS, et al. Salvianolic acid B inhibits low-density lipoprotein oxidation and neointimal hyperplasia in endothelium-denuded hypercholesterolaemic rabbits. J Sci Food Agric 2011; 91: 134-41.
25. Bao Y, Wang L, Xu Y, Yang Y, Wang L, Si S, et al. Salvianolic acid B inhibits macrophage uptake of modified low density lipoprotein (mLDL) in a scavenger receptor CD36-dependent manner. Atherosclerosis 2012; 223: 152-9.
26. Zhao GR, Zhang HM, Ye TX, Xiang ZJ, Yuan YJ, Guo ZX, et al. Characterization of the radical scavenging and antioxidant activities of danshensu and salvianolic acid B. Food Chem Toxicol 2008; 46: 73-81.
27. Liu X, Chen R, Shang Y, Jiao B, Huang C. Superoxide radicals scavenging and xanthine oxidase inhibitory activity of magnesium lithospermate B from Salvia miltiorrhiza. J Enzyme Inhib Med Chem 2009; 24: 663-8.
28. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011; 17: 1410-22.
29. Wu XJ, Wang YP, Wang W, Sun WK, Xu YM, Xuan LJ. Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B. Acta Pharmacol Sin 2000; 21: 855-8.
30. Zhang HS, Wang SQ. Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-alpha (TNF-alpha)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species. J Mol Cell Cardiol 2006; 41: 138-48.
31. Qu J, Ren X, Hou RY, Dai XP, Zhao YC, Xu XJ, et al. The protective effect of magnesium lithospermate B against glucose-induced intracellular oxidative damage. Biochem Biophys Res Commun 2011; 411: 32-9.
32. Wu HL, Li YH, Lin YH, Wang R, Li YB, Tie L, et al. Salvianolic acid B protects human endothelial cells from oxidative stress damage: a possible protective role of glucose-regulated protein 78 induction. Cardiovasc Res 2009; 81: 148-58.
33. Qui Y, Rui YC, Zhang L, Li TJ, Zhang WD. VEGF induced hyperpermeability in bovine aortic endothelial cell and inhibitory effect of salvianolic acid B. Acta Pharmacol Sin 2001; 22: 117-20. (Pubitemid 32158348)
34. Ding M, Ye TX, Zhao GR, Yuan YJ, Guo ZX. Aqueous extract of Salvia miltiorrhiza attenuates increased endothelial permeability induced by tumor necrosis factor-alpha. Int Immunopharmacol 2005; 5: 1641-51. (Pubitemid 41019435)
35. Ding M, Yuan YJ. Study on the mechanisms of an extract of Salvia miltiorrhiza on the regulation of permeability of endothelial cells exposed to tumour necrosis factor-alpha. J Pharm Pharmacol 2007; 59: 1027-33. (Pubitemid 47051085)
36. Shi CS, Huang HC, Wu HL, Kuo CH, Chang BI, Shiao MS, et al. Salvianolic acid B modulates hemostasis properties of human umbilical vein endothelial cells. Thromb Res 2007; 119: 769-75.
37. Zhou Z, Liu Y, Miao AD, Wang SQ. Salvianolic acid B attenuates plasminogen activator inhibitor type 1 production in TNF-alpha treated human umbilical vein endothelial cells. J Cell Biochem 2005; 96: 109-16. (Pubitemid 41420106)
38. Chen YH, Lin SJ, Ku HH, Shiao MS, Lin FY, Chen JW, et al. Salvianolic acid B attenuates VCAM-1 and ICAM-1 expression in TNF-alphatreated human aortic endothelial cells. J Cell Biochem 2001; 82: 512-21.
39. Xie LX, Durairajan SS, Lu JH, Liu CL, Kum WF, Wang Y, et al. The effect of salvianolic acid B combined with laminar shear stress on TNF-alpha-stimulated adhesion molecule expression in human aortic endothelial cells. Clin Hemorheol Microcirc 2010; 44: 245-58.
40. Chen SC, Lin YL, Huang B, Wang DL, Cheng JJ. Salvianolic acid B suppresses IFN-gamma-induced JAK/STAT1 activation in endothelial cells. Thromb Res 2011; 128: 560-4.
41. Joe Y, Zheng M, Kim HJ, Kim S, Uddin MJ, Park C, et al. Salvianolic acid B exerts vasoprotective effects through the modulation of heme Oxygenase-1 and arginase activities. J Pharmacol Exp Ther 2012; 341: 850-8.
42. Luo WB, Dong L, Wang YP. Effect of magnesium lithospermate B on calcium and nitric oxide in endothelial cells upon hypoxia/ reoxygenation. Acta Pharmacol Sin 2002; 23: 930-6.
43. Luo WB, Wang YP. Magnesium lithospermate B inhibits hypoxiainduced calcium influx and nitric oxide release in endothelial cells. Acta Pharmacol Sin 2001; 22: 1135-42.
44. Pan C, Lou L, Huo Y, Singh G, Chen M, Zhang D, et al. Salvianolic acid B and tanshinone IIA attenuate myocardial ischemia injury in mice by NO production through multiple pathways. Ther Adv Cardiovasc Dis 2011; 5: 99-111.
45. Sun A, Liu H, Wang S, Shi D, Xu L, Cheng Y, et al. Salvianolic acid B suppresses maturation of human monocyte-derived dendritic cells by activating PPARgamma. Br J Pharmacol 2011; 164: 2042-53.
46. Cheng CC, Yang SP, Lin WS, Ho LJ, Lai JH, Cheng SM, et al. Magnesium lithospermate B mediates anti-inflammation targeting activator protein-1 and nuclear factor-kappa B signaling pathways in human peripheral T lymphocytes. Int Immunopharmacol 2012; 13: 354-61.
47. Sperl B, Seifert MH, Berg T. Natural product inhibitors of proteinprotein interactions mediated by Src-family SH2 domains. Bioorg Med Chem Lett 2009; 19: 3305-9.
48. Won J, Hur YG, Hur EM, Park SH, Kang MA, Choi Y, et al. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lckdependent manner. Eur J Immunol 2003; 33: 870-9. (Pubitemid 36546674)
49. Wang L, Bao Y, Yang Y, Wu Y, Chen X, Si S, et al. Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like high-throughput screening assay. J Biomol Screen 2010; 15: 239-50.
50. Chen RJ, Jinn TR, Chen YC, Chung TY, Yang WH, Tzen JT. Active ingredients in Chinese medicines promoting blood circulation as Na+/K+-ATPase inhibitors. Acta Pharmacol Sin 2011; 32: 141-51.
51. Han B, Zhang X, Zhang Q, Zhao G, Wei J, Ma S, et al. Protective effects of salvianolate on microvascular flow in a porcine model of myocardial ischaemia and reperfusion. Arch Cardiovasc Dis 2011; 104: 313-24.
52. Jiang B, Wu W, Li M, Xu L, Sun K, Yang M, et al. Cardioprotection and matrix metalloproteinase-9 regulation of salvianolic acids on myocardial infarction in rats. Planta Med 2009; 75: 1286-92.
53. Xu L, Deng Y, Feng L, Li D, Chen X, Ma C, et al. Cardio-protection of salvianolic acid B through inhibition of apoptosis network. PLoS One 2011; 6: e24036.
54. Jiang B, Chen J, Xu L, Gao Z, Deng Y, Wang Y, et al. Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling. BMC Pharmacol 2010; 10: 10.
55. Wang Y, Xu F, Chen J, Shen X, Deng Y, Xu L, et al. Matrix metalloproteinase-9. induces cardiac fibroblast migration, collagen and cytokine secretion: inhibition by salvianolic acid B from Salvia miltiorrhiza. Phytomedicine 2011; 19: 13-9.
56. Lu Y, Liu X, Liang X, Xiang L, Zhang W. Metabolomic strategy to study therapeutic and synergistic effects of tanshinone IIA, salvianolic acid B and ginsenoside Rb1 in myocardial ischemia rats. J Ethnopharmacol 2011; 134: 45-9.
57. Lu Y, Zheng Y, Liu X, Liang X, Ngai S, Li T, et al. Metabolomic profiles of myocardial ischemia under treatment with salvianolic acid B. Chin Med 2012; 7: 6.
58. Wang W, Hu GY, Wang YP. Selective modulation of L-type calcium current by magnesium lithospermate B in guinea-pig ventricular myocytes. Life Sci 2006; 78: 2989-97. (Pubitemid 44294606)
59. Au-Yeung KK, Zhu DY, O K, Siow YL. Inhibition of stress-activated protein kinase in the ischemic/reperfused heart: role of magnesium tanshinoate B in preventing apoptosis. Biochem Pharmacol 2001; 62: 483-93. (Pubitemid 32607732)
60. Wang J, Zhang Y, Guo LL, Wu GJ, Liu RH. Salvianolic acid B inhibits the TLR4-NFkappaB-TNFalpha pathway and attenuates neonatal rat cardiomyocyte injury induced by lipopolysaccharide. Chin J Integr Med 2011; 17: 775-9.
61. Jiang B, Zhang L, Li M, Wu W, Yang M, Wang J, et al. Salvianolic acids prevent acute doxorubicin cardiotoxicity in mice through suppression of oxidative stress. Food Chem Toxicol 2008; 46: 1510-5.
62. Han X, Liu JX, Li XZ. Salvianolic acid B inhibits autophagy and protects starving cardiac myocytes. Acta Pharmacol Sin 2011; 32: 38-44.
63. Chen L, Xuan LJ, Wang YP. Effects of magnesium lithospermate B and its analogues on Ca2+ homeostasis in cultured rat thoracic aorta vascular smooth muscle cells. Planta Med 2009; 75: 1573-9.
64. Lam FF, Yeung JH, Kwan YW, Chan KM, Or PM. Salvianolic acid B, an aqueous component of danshen (Salvia miltiorrhiza), relaxes rat coronary artery by inhibition of calcium channels. Eur J Pharmacol 2006; 553: 240-5. (Pubitemid 44779601)
65. Zhang H, Zhang J, Zha R, Hu M, Wang Y. Magnesium lithospermate B decreases [Ca2+]i in endothelial cells by inhibiting K+ currents. Eur J Pharmacol 2011; 650: 285-9.
66. Lam FF, Seto SW, Kwan YW, Yeung JH, Chan P. Activation of the iberiotoxin-sensitive BKCa channels by salvianolic acid B of the porcine coronary artery smooth muscle cells. Eur J Pharmacol 2006; 546: 28-35. (Pubitemid 44331850)
67. Zhang HF, Chen XQ, Hu GY, Wang YP. Magnesium lithospermate B dilates mesenteric arteries by activating BKCa currents and contracts arteries by inhibiting KV currents. Acta Pharmacol Sin 2010; 31: 665-70.
68. Yang Q, Wang S, Xie Y, Wang J, Li H, Zhou X, et al. Effect of salvianolic Acid B and paeonol on blood lipid metabolism and hemorrheology in myocardial ischemia rabbits induced by pituitruin. Int J Mol Sci 2010; 11: 3696-704.
69. Wang F, Liu YY, Liu LY, Zeng QJ, Wang CS, Sun K, et al. The attenuation effect of 3,4-dihydroxy-phenyl lactic acid and salvianolic acid B on venular thrombosis induced in rat mesentery by photochemical reaction. Clin Hemorheol Microcirc 2009; 42: 7-18.
70. Wang W, Wang YP, Sun WK, Xu YM, Xuan LJ. Effects of magnesium lithospermate B on aggregation and 5-HT release in rabbit washed platelets. Acta Pharmacol Sin 2000; 21: 859-63.
71. Li M, Zhao C, Wong RN, Goto S, Wang Z, Liao F. Inhibition of shearinduced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B. Clin Hemorheol Microcirc 2004; 31: 97-103. (Pubitemid 39273876)
72. Wu YP, Zhao XM, Pan SD, Guo de A, Wei R, Han JJ, et al. Salvianolic acid B inhibits platelet adhesion under conditions of flow by a mechanism involving the collagen receptor alpha2beta1. Thromb Res 2008; 123: 298-305.
73. Ma C, Yao Y, Yue QX, Zhou XW, Yang PY, Wu WY, et al. Differential proteomic analysis of platelets suggested possible signal cascades network in platelets treated with salvianolic acid B. PLoS One 2011; 6: e14692.
74. Li XF, Wang YP. Depside salts from Salvia miltiorrhiza improve myocardial microperfusion in rats using laser Doppler flowmetry. Acta Pharmacol Sin 2007; 28: 789-95.
75. Kang DG, Oh H, Chung HT, Lee HS. Inhibition of angiotensin converting enzyme by lithospermic acid B isolated from radix Salviae miltiorrhiza Bunge. Phytother Res 2003; 17: 917-20. (Pubitemid 37152758)
76. Lu B, Ye Z, Deng Y, Wu H, Feng J. MEK/ERK pathway mediates cytoprotection of salvianolic acid B against oxidative stress-induced apoptosis in rat bone marrow stem cells. Cell Biol Int 2010; 34: 1063-8.
77. Chan SS, Chen JH, Hwang SM, Wang IJ, Li HJ, Lee RT, et al. Salvianolic acid B-vitamin C synergy in cardiac differentiation from embryonic stem cells. Biochem Biophys Res Commun 2009; 387: 723-8.
78. Chen YH, Du GH, Zhang JT. Salvianolic acid B protects brain against injuries caused by ischemia-reperfusion in rats. Acta Pharmacol Sin 2000; 21: 463-6.
79. Tzen JT, Jinn TR, Chen YC, Li FY, Cheng FC, Shi LS, et al. Magnesium lithospermate B possesses inhibitory activity on Na+,K+-ATPase and neuroprotective effects against ischemic stroke. Acta Pharmacol Sin 2007; 28: 609-15. (Pubitemid 46691096)
80. Li M, Zhao MQ, Kumar Durairajan SS, Xie LX, Zhang HX, Kum WF, et al. Protective effect of tetramethylpyrazine and salvianolic acid B on apoptosis of rat cerebral microvascular endothelial cell under high shear stress. Clin Hemorheol Microcirc 2008; 38: 177-87. (Pubitemid 351185405)
81. Durairajan SS, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, et al. Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochem Int 2008; 52: 741-50.
82. Kim DH, Park SJ, Kim JM, Jeon SJ, Cho YW, Son KH, et al. Cognitive dysfunctions induced by a cholinergic blockade and Abeta 25-35 peptide are attenuated by salvianolic acid B. Neuropharmacology 2011; 61: 1432-40.
83. Liu CL, Xie LX, Li M, Durairajan SS, Goto S, Huang JD. Salvianolic acid B inhibits hydrogen peroxide-induced endothelial cell apoptosis through regulating PI3K/Akt signaling. PLoS One 2007; 2: e1321.
84. Zeng G, Tang T, Wu HJ, You WH, Luo JK, Lin Y, et al. Salvianolic acid B protects SH-SY5Y neuroblastoma cells from 1-methyl-4-phenylpyridinium-induced apoptosis. Biol Pharm Bull 2010; 33: 1337-42.
85. Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002; 8: 679-85. (Pubitemid 34918663)
86. Lin YL, Wu CH, Luo MH, Huang YJ, Wang CN, Shiao MS, et al. In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells. J Ethnopharmacol 2006; 105: 215-22.
87. Paik YH, Yoon YJ, Lee HC, Jung MK, Kang SH, Chung SI, et al. Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Exp Mol Med 2011; 43: 341-9.
88. Tsai MK, Lin YL, Huang YT. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol Appl Pharmacol 2010; 242: 155-64.
89. Yao G, Xu L, Wu X, Yang J, Chen H. Preventive effects of salvianolic acid B on transforming growth factor-beta1-induced epithelial-tomesenchymal transition of human kidney cells. Biol Pharm Bull 2009; 32: 882-6.
90. Pan RH, Xie FY, Chen HM, Xu LZ, Wu XC, Xu LL, et al. Salvianolic acid B reverses the epithelial-to-mesenchymal transition of HK-2 cells that is induced by transforming growth factor-beta. Arch Pharm Res 2011; 34: 477-83.
91. Wang QL, Tao YY, Yuan JL, Shen L, Liu CH. Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-beta1 signal transduction pathway in vivo and in vitro. BMC Cell Biol 2010; 11: 31.
92. Chen CG, Wang YP. Magnesium lithospermate B ameliorates renal cortical microperfusion in rats. Acta Pharmacol Sin 2006; 27: 217-22.
93. Xu M, Wang YP, Luo WB, Xuan LJ. Salvianolate inhibits proliferation and endothelin release in cultured rat mesangial cells. Acta Pharmacol Sin 2001; 22: 629-33. (Pubitemid 32656492)
94. Luo P, Tan Z, Zhang Z, Li H, Mo Z. Inhibitory effects of salvianolic acid B on the high glucose-induced mesangial proliferation via NFkappaB-dependent pathway. Biol Pharm Bull 2008; 31: 1381-6. (Pubitemid 351930651)
95. Lee GT. Delayed treatment with lithospermate B attenuates experimental diabetic renal injury. J Am Soc Nephrol 2003; 14: 709-20. (Pubitemid 36246015)
96. Kang ES, Lee GT, Kim BS, Kim CH, Seo GH, Han SJ, et al. Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats. Eur J Pharmacol 2008; 579: 418-25.
97. Bulgakov VP, Inyushkina YV, Fedoreyev SA. Rosmarinic acid and its derivatives: biotechnology and applications. Crit Rev Biotechnol 2012; 32: 203-17.
98. Chu X, Ci X, He J, Jiang L, Wei M, Cao Q, et al. Effects of a natural prolyl oligopeptidase inhibitor, rosmarinic acid, on lipopolysaccharideinduced acute lung injury in mice. Molecules 2012; 17: 3586-98.
99. Kim DS, Kim HR, Woo ER, Hong ST, Chae HJ, Chae SW. Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signalregulated kinase. Biochem Pharmacol 2005; 70: 1066-78.
100. Karthik D, Viswanathan P, Anuradha CV. Administration of rosmarinic acid reduces cardiopathology and blood pressure through inhibition of p22phox NADPH oxidase in fructose-fed hypertensive rats. J Cardiovasc Pharmacol 2011; 58: 514-21.
101. Fadel O, El Kirat K, Morandat S. The natural antioxidant rosmarinic acid spontaneously penetrates membranes to inhibit lipid peroxidation in situ. Biochim Biophys Acta 2011; 1808: 2973-80.
102. Hur YG, Suh CH, Kim S, Won J. Rosmarinic acid induces apoptosis of activated T cells from rheumatoid arthritis patients via mitochondrial pathway. J Clin Immunol 2007; 27: 36-45. (Pubitemid 46224932)
103. Lee HJ, Jeong YI, Lee TH, Jung ID, Lee JS, Lee CM, et al. Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Biochem Pharmacol 2007; 73: 1412-21. (Pubitemid 46463948)
104. Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res 2007; 180: 139-45. (Pubitemid 46719420)
105. Jiang H, Song N, Xu H, Zhang S, Wang J, Xie J. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res 2010; 20: 345-56.
106. Du T, Li L, Song N, Xie J, Jiang H. Rosmarinic acid antagonized 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in MES23.5 dopaminergic cells. Int J Toxicol 2010; 29: 625-33.
107. Wang J, Xu H, Jiang H, Du X, Sun P, Xie J. Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson's disease. J Mol Neurosci 2012; 47: 113-9.
108. Jiang WL, Xu Y, Zhang SP, Hou J, Zhu HB. Effect of rosmarinic acid on experimental diabetic nephropathy. Basic Clin Pharmacol Toxicol 2012; 110: 390-5.
109. Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, et al. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor gamma in hepatic stellate cells for their antifibrotic effect. Hepatology 2012; 55: 1271-81.
110. Liu X, Chen R, Shang Y, Jiao B, Huang C. Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats. Chem Biol Interact 2008; 176: 137-42.
111. Chen L, Wang WY, Wang YP. Inhibitory effects of lithospermic acid on proliferation and migration of rat vascular smooth muscle cells. Acta Pharmacol Sin 2009; 30: 1245-52.